---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041367"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:07:53.344307+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10

## Summary
- Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
- Company requested immediate review and stay by Listing Council; Nasdaq counsel refused, but company claims precedent exists for such stays.
- If suspended, BCAB is expected to trade on OTC under same symbol, which may materially affect trading price and volume.
- As of Feb 6, $1.25M principal remained outstanding under Pre-Paid Advance Agreements; SEPA prohibits share sales during suspension.
- Company asserts Nasdaq improperly delayed compliance confirmation and secretly overturned long-standing reverse stock split policy.

## SEC filing metadata
- accession: 0001193125-26-041367
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/0001193125-26-041367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/bcab-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041367
- JSON: https://secwatch.observer/filing/0001193125-26-041367.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041367.txt

## Source-grounded claims
- claim_id: 05e00a0165b27c2b75b733c4f4985a767cc6c29c
  claim: BioAtla, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/0001193125-26-041367-index.htm
- claim_id: c2c23c956d4188a849665f1435c751a5926b7ee6
  claim: BioAtla, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/0001193125-26-041367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.